Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 19/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | CTSD | P07339 | 1/20 | 0.65 |
| ▸ | CTSE | P14091 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938126 | 0.93 | REN (1.00) | RENCYP3A4CTSDCTSE | |
| SCHEMBL4934349 | 0.92 | REN (1.00) | RENCYP3A4CTSDCTSE | |
| SCHEMBL4930898 | 0.86 | REN (0.82) | RENCYP3A4CTSDCTSE | |
| SCHEMBL4934245 | 0.83 | REN (0.73) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5942101 | 0.82 | REN (0.92) | RENCYP3A4CTSDCTSE | |
| SCHEMBL8227615 | 0.81 | REN (0.67) | RENCYP3A4CTSDCTSE | |
| SCHEMBL8231250 | 0.80 | REN (0.66) | RENCYP3A4CTSDCTSE | |
| Formic Acid SCHEMBL5941575 | 0.80 | REN (0.87) | RENCYP3A4CTSDCTSE | |
| SCHEMBL13232947 | 0.79 | REN (0.65) | RENCYP3A4CTSDCTSE | |
| SCHEMBL4983278 | 0.79 | REN (1.00) | RENCYP3A4CTSDCTSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234305-A1 | Novel Tetrahydropyridine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-25 | — | — | US | claimed |
| US-20080234305-A1 | Novel Tetrahydropyridine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234305-A1 | Novel Tetrahydropyridine Derivatives | REN, AGTR1, CBR1 | REN 1/4885CYP3A4 115/4885CTSD 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.